Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

34
Avoid Reinsurance Group, Add These Top 4 Insurance Stocks

2018-06-20 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) has been witnessing southbound revisions of late. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 7.3% downward while for 2019, the consensus mark moved nearly 0.4% south. The stock carries a Zacks Rank #4 (Sell) with an unimpressive VGM Score of C. Back tested results show that stocks with a favorable VGM Score of A or B when combined with a bullish Zacks Rank #1 (Strong Buy) or 2 (Buy), comfortably outperform other stocks.
AFL RGA PGR NAVG 8686 AFSD

0
Moving Average Crossover Alert: Reinsurance Group of America (RGA)

2018-06-19 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for RGA broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness.
RGA

3
Reinsurance Group Of America (RGA) Investor Presentation - Slideshow

2018-06-08 seekingalpha
The following slide deck was published by Reinsurance Group of America, Incorporated in conjunction with this event.
RGA RZB RZA

3
Reinsurance Group Of America (RGA) Investor Presentation - Slideshow

2018-06-08 seekingalpha
The following slide deck was published by Reinsurance Group of America, Incorporated in conjunction with this event.
RGA RZB RZA

0
RGA / Reinsurance Group of America, Inc. FORM 8-K (Current Report)

2018-06-07 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RGA

936
1
Reinsurance Group of America (RGA) Down 5.6% Since Earnings Report: Can It Rebound?

2018-05-28 zacks
A month has gone by since the last earnings report for Reinsurance Group of America, Incorporated (RGA - Free Report) . Shares have lost about 5.6% in that time frame.
DUKH RGA DUK SAVE

0
RGA / Reinsurance Group of America, Inc. FORM 8-K (Current Report)

2018-05-25 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RGA

0
RGA / Reinsurance Group of America, Inc. FORM 8-K (Current Report)

2018-05-17 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RGA

4
Should SPDR S&P 400 Mid Cap Value ETF (MDYV) Be on Your Investing Radar?

2018-05-14 zacks
Looking for broad exposure to the Mid Cap Value segment of the US equity market? You should consider the SPDR S&P 400 Mid Cap Value ETF (MDYV - Free Report) , a passively managed exchange traded fund launched on 11/08/2005.
STLD MDYV IWS HFC VOE RGA RZB RZA

4
Primerica (PRI) Q1 Earnings Miss Estimates, Improve Y/Y

2018-05-10 zacks
Primerica, Inc. (PRI - Free Report) reported first-quarter 2018 operating income of $1.47 per share, missing the Zacks Consensus Estimate of $1.49 by nearly 1.3%. However, the bottom line improved 32.4% year over year on lower effective tax rate (from the legislation of the Tax Cuts and Jobs Act of 2017). Also, ongoing share buybacks offered an additional upside to the bottom line.
TMK LNC TMK.PRC TMK.PRB PRI RGA LNC.WS TMK

10
Sun Life's (SLF) Q1 Earnings Up on Solid Segmental Growth

2018-05-09 zacks
Sun Life Financial Inc. (SLF - Free Report) reported first-quarter 2018 underlying net income of $609 million (C$770 million), up 14.5% year over year. This improvement was fueled by interest on par seed capital, strong business growth, the lower U.S. income tax rate and favorable investment experience.
TMK SLF LNC.WS TMK SLF LNC TMK.PRC TMK.PRB GM.WS.A GM.WS.B RGA GM.WS.C SLF.PR.G SLFYF GM GM.WSB SLF.PR.B SLF.PR.E SLF.PR.D SLF

1
RGA / Reinsurance Group of America, Inc. 10-Q (Quarterly Report)

2018-05-04 sec.gov
Document Table of Contents
RGA

41
Manulife (MFC) Q1 Earnings Grow on Strong Segmental Results

2018-05-03 zacks
Manulife Financial Corporation (MFC - Free Report) reported first-quarter 2018 core earnings of $1.03 billion (C$1,303 million), up 22% year over year. This upside stemmed from higher investment-related experience gains in core earnings, strong growth in Asia and Global Wealth and Asset Management, improved policyholder experience in Canada and a favorable impact of lower U.S. tax rates.
MFC.PR.B FISI MFC.PR.F MFC.PR.C LNC.WS AVP FIISO FIISP MFC LNC 0945 RSG RGA MFC.PR.I MFC.PR.J MFC MFC.PR.H GNW MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to RGA / Reinsurance Group of America, Inc. on message board site Silicon Investor.

Margaret Sangeru0027s Eugenic Legacy of Death, Disease, Depravit J.P. Morgan Chase (JPM)
Airgain (AIRG) J P Morgan Chase
Kinder Morgan Inc-(KMI) Organovo (ONVO)
Light Emitting Devices, organic and novel JP Morgan Chase u0026 Co.
Shopping For The Ultimate Bargains Kinder Morgan Energy Partners (KMP)
CUSIP: 759351604